Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 5, 2002, Pages 483-488

  Kadish, Anna S ^a   Timmins, Patrick ^a   Wang, Yuexian ^a   Ho, Gloria Y F ^a   Burk, Robert D ^a   Ketz, John ^a   He, Wu ^a   Romney, Seymour L ^a   Johnson, Anne ^a   Angeletti, Ruth ^a   Abadi, Maria ^a   Anderson, Patrick ^a   Budnick, Lairie ^a   Burke, Ronald ^a   Cass, Ilana ^a   Hutchinson Colas, Juana ^a   Fields, Abbie ^a   Kaali, Olga ^a   Mikhail, Magdy ^a   Nazan, Serge ^a   Roche, Natalie ^a   Runowics, Carolyn ^a   Simbala, Carlos ^a   Wilian, Daryl ^a   Hennessy, Marianne ^a   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; CELLULAR IMMUNITY; COLPOSCOPY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VERRUCA VULGARIS; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS TYPING; WART VIRUS;

ADULT; AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNITY, CELLULAR; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM STAGING; NEW YORK; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; SENSITIVITY AND SPECIFICITY; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; WOMEN'S HEALTH;

EID: 0036097767     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Natural history of cervicovaginal papillomavirus infection in young women
2. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: Results from a case-control study conducted in the United States
3. HPV 16 infection and progression of cervical intra-epithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants
4. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
5. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
6. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression
7. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women
8. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women
9. Cell mediated immune response to HPV16 E7 peptides are dependent on HPV type infecting the cervix, whereas serologic reactivity is not type specific
10. Lymphoproliferative cell-mediated immune responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia
11. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia
12. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection
13. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study
14. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia
15. Cytokine production patterns in cervical intraepithelial neoplasia: Association with human papillomavirus infection
16. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix
17. Regional immunosuppression in esophageal squamous cancer: Evidence from functional studies with matched lymph nodes
18. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
19. Induction of cytotoxic T lymphocytes specific for an syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
20. Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate TR-cell epitopes in human papilloma virus
21. The Bethesda System, the pathology of preinvasive lesions, and screening technology. The Bethesda System (TBS) of nomenclature for cervical smears
22. Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: Correlation with biopsy results and Papanicolaou smear
23. Sexual practices and partner characteristics are the predominant risk factors for genital HPV infection in young women
24. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
25. Stringent criteria for histologic diagnosis of koilocytosis fail to eliminate overdiagnosis of human papillomavirus infection and cervical intraepithelial neoplasia grade I
26. Natural history of cervical intraepithelial neoplasia: A critical review
27. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
28. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
29. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif
30. Natural T-helper immunity against human papillomavirus type 16 (HPV 16) E7-derived peptide epitopes in patients with HPV 16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes
31. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16
32. Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules
33. The role of CD4+ T cell responses in antitumor immunity